Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

A "RANning" leap with "XPOrt" into TKI resistance.

Rassool F, Perrotti D.

Blood. 2015 Mar 12;125(11):1686-8. doi: 10.1182/blood-2015-01-622217. No abstract available.

2.

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.

Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, O'Hare T, Deininger MW.

Blood. 2015 Mar 12;125(11):1772-81. doi: 10.1182/blood-2014-08-588855. Epub 2015 Jan 8.

3.

c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.

Lucas CM, Harris RJ, Giannoudis A, Clark RE.

Haematologica. 2015 May;100(5):e179-82. doi: 10.3324/haematol.2014.115691. Epub 2015 Feb 6. No abstract available.

4.

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.

Wöhrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P, Schramek D, Penninger JM, Laßmann S, Werner M, Waller CF, Pahl HL, Zeiser R, Daly RJ, Brummer T.

Leukemia. 2013 Jan;27(1):118-29. doi: 10.1038/leu.2012.222. Epub 2012 Aug 3.

PMID:
22858987
5.

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.

Mahon FX, Hayette S, Lagarde V, Belloc F, Turcq B, Nicolini F, Belanger C, Manley PW, Leroy C, Etienne G, Roche S, Pasquet JM.

Cancer Res. 2008 Dec 1;68(23):9809-16. doi: 10.1158/0008-5472.CAN-08-1008.

6.

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.

Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.

Autophagy. 2015;11(2):355-72. doi: 10.4161/15548627.2014.994368.

7.

Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.

Xiao M, Ai H, Li T, Rajoria P, Shahu P, Li X.

Biochem Biophys Res Commun. 2016 Apr 15;472(4):610-6. doi: 10.1016/j.bbrc.2016.03.018. Epub 2016 Mar 8.

PMID:
26966074
8.

Request for retraction: Short interfering RNA (siRNA) as a novel therapeutic.

Melendez-Romero A.

Clin Exp Pharmacol Physiol. 2013 Apr;40(4):305. doi: 10.1111/1440-1681.12073. No abstract available.

PMID:
23551129
9.

Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.

O'Dwyer ME, Druker BJ.

Curr Opin Oncol. 2000 Nov;12(6):594-7. Review.

PMID:
11085460
10.

Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.

Li Q, Huang Z, Gao M, Cao W, Xiao Q, Luo H, Feng W.

Int J Mol Sci. 2017 Mar 2;18(3). pii: E537. doi: 10.3390/ijms18030537.

11.

Request for the retraction of Cepp review 33: 504-510 (2006).

Pushparaj P.

Clin Exp Pharmacol Physiol. 2013 Apr;40(4):305. doi: 10.1111/1440-1681.12077. No abstract available.

PMID:
23551130
12.

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.

Halbach S, Hu Z, Gretzmeier C, Ellermann J, Wöhrle FU, Dengjel J, Brummer T.

Cell Commun Signal. 2016 Feb 24;14:6. doi: 10.1186/s12964-016-0129-y.

13.

A case with coexistence of major and minor BCR/ABL fusion transcript at lymphoblastic crisis of chronic myelogenous leukemia in patients with major BCR/ABL positivity during chronic phase.

Park SH, Chi HS, Cho YU, Jang S, Park CJ, Im HJ.

Ann Lab Med. 2013 Jan;33(1):80-3. doi: 10.3343/alm.2013.33.1.80. Epub 2012 Dec 17. No abstract available.

14.

RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.

Withey JM, Harvey AJ, Crompton MR.

Leuk Res. 2006 May;30(5):553-60. Epub 2005 Nov 2.

PMID:
16260034
15.

Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.

Burchert A.

Curr Hematol Malig Rep. 2014 Mar;9(1):9-16. doi: 10.1007/s11899-013-0196-8. Review.

16.

Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.

Lee CR, Kang JA, Kim HE, Choi Y, Yang T, Park SG.

FEBS Lett. 2016 Feb;590(3):358-68. doi: 10.1002/1873-3468.12057. Epub 2016 Jan 25.

17.

Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.

Sears D, Luong P, Yuan M, Nteliopoulos G, Man YK, Melo JV, Basu S.

Cell Death Dis. 2010 Nov 4;1:e93. doi: 10.1038/cddis.2010.72.

18.

Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?

Kelani R, Monem F.

Int J Lab Hematol. 2015 Oct;37(5):723-8. doi: 10.1111/ijlh.12394. Epub 2015 Jun 9.

PMID:
26059167
19.

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.

Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.

Leukemia. 2005 Oct;19(10):1774-82.

PMID:
16136169
20.

Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.

O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ.

Cancer Res. 2013 Jun 1;73(11):3356-70. doi: 10.1158/0008-5472.CAN-12-3904. Epub 2013 Apr 10.

Supplemental Content

Support Center